Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0YSQTB
ADC Name	mesoADC
Synonyms	meso ADC; meso-ADC Click to Show/Hide
Drug Status	Investigative
Indication	In total 2 Indication(s) Breast cancer [ICD11:2C60-2C65] Investigative Colorectal cancer [ICD11:2B91] Investigative
	3D MOL	2D MOL
Antibody Name	Anti-GSDME mAb		Antibody Info
Antigen Name	Gasdermin-E (GSDME)		Antigen Info
Payload Name	Monomethyl auristatin E		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	Mc-Val-Cit-PABC		Linker Info
Conjugate Type	Random conjugation through reduced inter-chain cysteines.
Combination Type	Vedotin

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 88.8	%	EMT6 cells	Mammary gland malignant neoplasms

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	0.25	ug/mL	EMT6 cells	Mammary gland malignant neoplasms
Half Maximal Inhibitory Concentration (IC50)	9.5	ug/mL	CT26 cells	Colon carcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 88.80% (Day 18)	High GSDME expression (GSDME +++)
Method Description	Comparison of the maximum tested dose of mesoADC (4.4 mg/kg) to PBS vehicle or isotype control ADC confirmed the antitumor effectiveness of the ADC up to day 18 .
In Vivo Model	EMT6 CDX model
In Vitro Model	Mammary gland malignant neoplasms	EMT6 cells		CVCL_1923

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.25 ug/mL	High GSDME expression (GSDME +++)
Method Description	EMT6 cells were pulsed with 1 ug/mL mesoADC for 30min then chased for 30 and 60min at 37°C.
In Vitro Model	Mammary gland malignant neoplasms	EMT6 cells		CVCL_1923
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	9.50 ug/mL	Low GSDME expression (GSDME +)
Method Description	CT26 cells were pulsed with 1 ug/mL mesoADC for 30min then chased for 30 and 60min at 37°C.
In Vitro Model	Colon carcinoma	CT26 cells		CVCL_7254

References

Ref 1	An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer. J Immunother Cancer. 2023 Mar;11(3):e006274. doi: 10.1136/jitc-2022-006274.